In Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., No. 13-854, slip op. 574 U.S. __ (2015), the U.S. Supreme Court ruled that underlying factual issues resolved while formally construing a disputed patent claim term at the...more
1/30/2015
/ Claim Construction ,
De Novo Standard of Review ,
Extrinsic Evidence ,
Hatch-Waxman ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
SCOTUS ,
Standard of Review ,
Teva Pharmaceuticals ,
Teva v Sandoz